Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06644768 · ClinicalTrials.gov registry record · Phase 1
A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations
A Phase 1 study of Non-Small Cell Lung Cancer and Lung Cancer, sponsored by Daiichi Sankyo.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 137
- Enrollment target
- 20
- Study locations
NCT06644768: Recruiting Phase 1 study of Non-Small Cell Lung Cancer and Lung Cancer, sponsored by Daiichi Sankyo.
NCT06644768 is a Phase 1 study of Non-Small Cell Lung Cancer and Lung Cancer that is actively recruiting participants, run by Daiichi Sankyo. The registered enrollment target is 137 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (79% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06644768, a Phase 1 study of Non-Small Cell Lung Cancer and Lung Cancer, is actively recruiting participants, sponsored by Daiichi Sankyo.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 137 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will compare Valemetostat Tosylate Plus Pembrolizumab vs Pembrolizumab Alone in First-line NSCLC Without Actionable Genomic Alterations
Primary Outcome
Total number of participants with A Dose-Limiting Toxicity (DLT) at each dose level of valemetostat in combination with pembrolizumab per National Cancer Institute - Common Terminology Criteria for Adverse Events version 5.0.
Conditions Studied
Interventions
- DRUG pembrolizumab
- DRUG valemetostat tosylate
Study Locations (20)
Other
- Hospital Italiano de Buenos Aires - Buenos Aires
- Instituto Alexander Fleming - Buenos Aires
- Sanatorio Allende - Córdoba
- Fundacion Ars Medica - N Salvador de Jujuy
- Centro de Investigacion Pergamino Sa - Pergamino
- Instituto Medico de La Fundacion Estudios Clinicos - Rosario
- Clinica Viedma S.A. - Viedma
- Centro de Pesquisas Clinica Reichow - Blumenau
California
- University of California San Diego (Ucsd)-Moores Cancer Center - La Jolla
- California Research Institute - Los Angeles
- Valkyrie Clinical Trials - Los Angeles
Florida
- Mayo Clinic Hospital - Jacksonville
- BRCR Global - Plantation
Kentucky
- University of Kentucky Medical Center - Lexington
- Pikeville Medical Center - Pikeville
New York
- Columbia University Irving Medical Center - New York
- Montefiore Medical Center - The Bronx
Minnesota
- Mayo Clinic - Rochester - Rochester
Pennsylvania
- Thomas Jefferson University, Sidney Kimmel Cancer Center - Philadelphia
Virginia
- Virginia Cancer Specialist - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 137 participants |
| Start Date | 2024-10-30 |
| Est. Completion | 2030-04-30 |
| Phase | Phase 1 |
What NCT06644768 shows while recruiting
NCT06644768 is an interventional study that assigns participants to a tested intervention. The registered 137 participants enrollment target is mid-sized for trials with a published cap, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (79% lower).
The record links to 2 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which pembrolizumab is the first listed.
NCT06644768 names 20 study sites across 8 states, led by Other, California, Florida.
Frequently Asked Questions
What is clinical trial NCT06644768 about?
NCT06644768 is a clinical study titled "A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations". This study will compare Valemetostat Tosylate Plus Pembrolizumab vs Pembrolizumab Alone in First-line NSCLC Without Actionable Genomic Alterations
What is the current status of trial NCT06644768?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 137 participants. The study started on 2024-10-30. Estimated completion is 2030-04-30.
What conditions does trial NCT06644768 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Lung Cancer.
What interventions are being tested in trial NCT06644768?
The interventions under investigation include: pembrolizumab (DRUG), valemetostat tosylate (DRUG).
Who is sponsoring clinical trial NCT06644768?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06644768 being conducted?
This trial has 20 study locations across California, Florida, Kentucky, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06644768's enrollment target sits among peer trials
137 209th of 454 higher than 246 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05091424 · 137 participants · Phase 1
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
- NCT05655182 · 137 participants · Phase 1
A Study of BLB-201 RSV Vaccine in Infants and Children
- NCT06571669 · 137 participants · NA
BOOM-IBD2 Pivotal Clinical Trial
- NCT07351071 · 137 participants · NA
Post-Market Study of the Signia Circular Stapler With Tri-Staple Technology in Left-sided Colon, Sigmoid, and Rectal Resections
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI